Proposed Information Collection Activity; Screening Tool for Unaccompanied Children Program Staff and Visitors (0970-0543), 44023-44024 [2021-17255]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 152 / Wednesday, August 11, 2021 / Notices
jbell on DSKJLSW7X2PROD with NOTICES
those who subscribe to receive email
updates about ACIP.
Purpose: The committee is charged
with advising the Director, CDC, on the
use of immunizing agents. In addition,
under 42 U.S.C. 1396s, the committee is
mandated to establish and periodically
review and, as appropriate, revise the
list of vaccines for administration to
vaccine-eligible children through the
Vaccines for Children (VFC) program,
along with schedules regarding dosing
interval, dosage, and contraindications
to administration of vaccines. Further,
under provisions of the Affordable Care
Act, section 2713 of the Public Health
Service Act, immunization
recommendations of the ACIP that have
been approved by the Director of the
Centers for Disease Control and
Prevention and appear on CDC
immunization schedules must be
covered by applicable health plans.
Matters To Be Considered: The agenda
will include discussions on additional
doses of COVID–19 vaccine, including
booster doses. A recommendation vote
is scheduled. Agenda items are subject
to change as priorities dictate. For more
information on the meeting agenda visit
https://www.cdc.gov/vaccines/acip/
meetings/meetings-info.html.
Meeting Information: The meeting
will be webcast live via the World Wide
Web; for more information on ACIP
please visit the ACIP website: https://
www.cdc.gov/vaccines/acip/.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
Written Public Comment: Written
comments must be received on or before
August 13, 2021.
VerDate Sep<11>2014
23:05 Aug 10, 2021
Jkt 253001
Oral Public Comment: This meeting
will include time for members of the
public to make an oral comment. Oral
public comment will occur before any
scheduled votes including all votes
relevant to the ACIP’s Affordable Care
Act and Vaccines for Children Program
roles. Priority will be given to
individuals who submit a request to
make an oral public comment before the
meeting according to the procedures
below.
Procedure for Oral Public Comment:
All persons interested in making an oral
public comment at the August 13, 2021,
ACIP meeting must submit a request at
https://www.cdc.gov/vaccines/acip/
meetings/ no later than 11:59 p.m., EDT,
August 11, 2021, according to the
instructions provided.
If the number of persons requesting to
speak is greater than can be reasonably
accommodated during the scheduled
time, CDC will conduct a lottery to
determine the speakers for the
scheduled public comment session.
CDC staff will notify individuals
regarding their request to speak by email
by 12:00 p.m., EDT, August 12, 2021. To
accommodate the significant interest in
participation in the oral public
comment session of ACIP meetings,
each speaker will be limited to 3
minutes, and each speaker may only
speak once per meeting.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–17266 Filed 8–9–21; 4:15 pm]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
ACTION:
Request for public comment.
The Office of Refugee
Resettlement (ORR), Administration for
Children and Families (ACF), U.S.
Department of Health and Human
Services (HHS), is proposing to continue
use of a coronavirus (COVID–19)
screening tool for unaccompanied
children (UC) program staff and visitors
at ORR care provider facilities.
SUMMARY:
Comments due within 60 days of
publication. In compliance with the
requirements of the Paperwork
Reduction Act of 1995, ACF is soliciting
public comment on the specific aspects
of the information collection described
above.
DATES:
Copies of the proposed
collection of information can be
obtained and comments may be
forwarded by emailing infocollection@
acf.hhs.gov. Alternatively, copies can
also be obtained by writing to the
Administration for Children and
Families, Office of Planning, Research,
and Evaluation (OPRE), 330 C Street
SW, Washington, DC 20201, Attn: ACF
Reports Clearance Officer. All requests,
emailed or written, should be identified
by the title of the information collection.
ADDRESSES:
SUPPLEMENTARY INFORMATION:
Description: The COVID–19 Verbal
Screening and Temperature Check tool
is verbally administered to all staff and
visitors before they are granted access
an ORR care provider facility. The tool
asks whether the individual displays
COVID–19 symptoms, has had close
contact with individuals known to test
positive for COVID–19, has been tested
for COVID–19, has been exposed to
someone known or suspected to be
infected with COVID–19, or has been
tested for COVID–19. The tool also
requests a temperature check. The
information collected by administering
this screening tool will help ensure the
health and safety of children and staff
at care provider facilities by helping to
identify and reduce potential exposure
to COVID–19.
Respondents: Staff and visitors at
ORR care provider programs.
Proposed Information Collection
Activity; Screening Tool for
Unaccompanied Children Program
Staff and Visitors (0970–0543)
Office of Refugee Resettlement,
Administration for Children and
Families, Department of Health and
Human Services.
AGENCY:
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
44023
E:\FR\FM\11AUN1.SGM
11AUN1
44024
Federal Register / Vol. 86, No. 152 / Wednesday, August 11, 2021 / Notices
ANNUAL BURDEN ESTIMATES
Instrument
Total
number of
respondents
Annual
responses per
respondent
Average
burden hours
per response
Annual
burden hours
COVID–19 Verbal Screening and Temperature Check ..................................
15,000
260
.033
128,700
Comments: The Department
specifically requests comments on (a)
whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) the quality, utility,
and clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Consideration will be given
to comments and suggestions submitted
within 60 days of this publication.
Authority: 6 U.S.C. 279.
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2021–17255 Filed 8–9–21; 4:15 pm]
BILLING CODE 4184–45–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–N–0008]
Request for Nominations for
Individuals and Consumer
Organizations for Advisory
Committees
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
requesting that any consumer
organizations interested in participating
in the selection of voting and/or
nonvoting consumer representatives to
serve on its advisory committees or
panels notify FDA in writing. FDA is
also requesting nominations for voting
and/or nonvoting consumer
representatives to serve on advisory
committees and/or panels for which
vacancies currently exist or are expected
to occur in the near future. Nominees
recommended to serve as a voting or
nonvoting consumer representative may
be self-nominated or may be nominated
by a consumer organization. FDA seeks
to include the views of women and
men, members of all racial and ethnic
groups, and individuals with and
without disabilities on its advisory
committees and, therefore, encourages
nominations of appropriately qualified
candidates from these groups.
DATES: Any consumer organization
interested in participating in the
selection of an appropriate voting or
nonvoting member to represent
consumer interests on an FDA advisory
committee or panel may send a letter or
email stating that interest to FDA (see
ADDRESSES) by September 27, 2021, for
vacancies listed in this notice.
Concurrently, nomination materials for
prospective candidates should be sent to
FDA (see ADDRESSES) by September 27,
2021. Nominations will be accepted for
current vacancies and for those that will
or may occur through December 31,
2021.
SUMMARY:
All statements of interest
from consumer organizations interested
in participating in the selection process
should be submitted electronically to
ACOMSSubmissions@fda.hhs.gov or by
mail to Advisory Committee Oversight
and Management Staff, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 5122, Silver Spring,
MD 20993–0002.
Consumer representative nominations
should be submitted electronically by
logging into the FDA Advisory
Committee Membership Nomination
Portal: https://www.accessdata.fda.gov/
scripts/FACTRSPortal/FACTRS/
index.cfm, or by mail to Advisory
Committee Oversight and Management
Staff, 10903 New Hampshire Ave., Bldg.
32, Rm. 5122, Silver Spring, MD 20993–
0002. Additional information about
becoming a member of an FDA advisory
committee can also be obtained by
visiting FDA’s website at https://
www.fda.gov/AdvisoryCommittees/
default.htm.
ADDRESSES:
For
questions relating to participation in the
selection process: Kimberly Hamilton,
Advisory Committee Oversight and
Management Staff, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 5122, Silver Spring,
MD 20993–0002, 301–796–8220,
kimberly.hamilton@fda.hhs.gov.
For questions relating to specific
advisory committees or panels, contact
the appropriate Contact Person listed in
table 1.
FOR FURTHER INFORMATION CONTACT:
TABLE 1—ADVISORY COMMITTEE CONTACTS
jbell on DSKJLSW7X2PROD with NOTICES
Contact person
Committee/panel
Rakesh Raghuwanshi, Office of the Chief Scientist, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 3309, Silver
Spring, MD 20993–0002, 301–796–4769, Rakesh.Raghuwanshi@
fda.hhs.gov.
Christina Vert, Center for Biologics Evaluation and Research, Food and
Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm.
6268, Silver Spring, MD 20993–0002, 240–402–8054,
Christina.Vert@fda.hhs.gov.
Jarrod Collier, Center for Biologics Evaluation and Research, Food and
Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Silver
Spring, MD 20993–0002, 202–906–0043, Jarrod.Collier@
fda.hhs.gov.
VerDate Sep<11>2014
23:05 Aug 10, 2021
Jkt 253001
PO 00000
Frm 00037
Fmt 4703
FDA Science Board Advisory Committee.
Blood Products Advisory Committee.
Cellular, Tissue and Gene Therapies Advisory Committee.
Sfmt 4703
E:\FR\FM\11AUN1.SGM
11AUN1
]]>Agencies
[Federal Register Volume 86, Number 152 (Wednesday, August 11, 2021)]
[Notices]
[Pages 44023-44024]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-17255]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Children and Families
Proposed Information Collection Activity; Screening Tool for
Unaccompanied Children Program Staff and Visitors (0970-0543)
AGENCY: Office of Refugee Resettlement, Administration for Children and
Families, Department of Health and Human Services.
ACTION: Request for public comment.
-----------------------------------------------------------------------
SUMMARY: The Office of Refugee Resettlement (ORR), Administration for
Children and Families (ACF), U.S. Department of Health and Human
Services (HHS), is proposing to continue use of a coronavirus (COVID-
19) screening tool for unaccompanied children (UC) program staff and
visitors at ORR care provider facilities.
DATES: Comments due within 60 days of publication. In compliance with
the requirements of the Paperwork Reduction Act of 1995, ACF is
soliciting public comment on the specific aspects of the information
collection described above.
ADDRESSES: Copies of the proposed collection of information can be
obtained and comments may be forwarded by emailing
[email protected]. Alternatively, copies can also be obtained
by writing to the Administration for Children and Families, Office of
Planning, Research, and Evaluation (OPRE), 330 C Street SW, Washington,
DC 20201, Attn: ACF Reports Clearance Officer. All requests, emailed or
written, should be identified by the title of the information
collection.
SUPPLEMENTARY INFORMATION:
Description: The COVID-19 Verbal Screening and Temperature Check
tool is verbally administered to all staff and visitors before they are
granted access an ORR care provider facility. The tool asks whether the
individual displays COVID-19 symptoms, has had close contact with
individuals known to test positive for COVID-19, has been tested for
COVID-19, has been exposed to someone known or suspected to be infected
with COVID-19, or has been tested for COVID-19. The tool also requests
a temperature check. The information collected by administering this
screening tool will help ensure the health and safety of children and
staff at care provider facilities by helping to identify and reduce
potential exposure to COVID-19.
Respondents: Staff and visitors at ORR care provider programs.
[[Page 44024]]
Annual Burden Estimates
----------------------------------------------------------------------------------------------------------------
Annual Average burden
Instrument Total number of responses per hours per Annual burden
respondents respondent response hours
----------------------------------------------------------------------------------------------------------------
COVID-19 Verbal Screening and Temperature 15,000 260 .033 128,700
Check......................................
----------------------------------------------------------------------------------------------------------------
Comments: The Department specifically requests comments on (a)
whether the proposed collection of information is necessary for the
proper performance of the functions of the agency, including whether
the information shall have practical utility; (b) the accuracy of the
agency's estimate of the burden of the proposed collection of
information; (c) the quality, utility, and clarity of the information
to be collected; and (d) ways to minimize the burden of the collection
of information on respondents, including through the use of automated
collection techniques or other forms of information technology.
Consideration will be given to comments and suggestions submitted
within 60 days of this publication.
Authority: 6 U.S.C. 279.
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2021-17255 Filed 8-9-21; 4:15 pm]
BILLING CODE 4184-45-P
